DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.69
-0.05 (-0.57%)
Oct 27, 2026, 4:00 PM EDT - Market closed
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
35
Market Cap
468.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arvinas | 316.70M |
| Phathom Pharmaceuticals | 239.66M |
| CytomX Therapeutics | 18.30M |
| Surrozen | 11.51M |
| Oculis Holding AG | 1.45M |
| Neurogene | 925.00K |
| Entera Bio | 42.00K |
DMAC News
- 5 days ago - DiaMedica announces enrollment of 200th patient in ReMEDy2 Phase 2/3 trial - TheFly
- 5 days ago - DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire
- 8 days ago - DiaMedica Therapeutics provides update on FGR trial at KOL event - TheFly
- 8 days ago - DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - Business Wire
- 27 days ago - DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results - Business Wire
- 7 weeks ago - DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences - Business Wire
- 2 months ago - DiaMedica Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - DiaMedica Therapeutics Quarterly report: Q2 2026 - Filings